Depomed (NYSE:ASRT) Stock Price Down 16.9%
Depomed, Inc. (NYSE:ASRT)’s share price traded down 16.9% on Tuesday . The stock traded as low as $1.27 and last traded at $1.33, 6,257,434 shares changed hands during mid-day trading. An increase of 545% from the average session volume of 969,680 shares. The stock had previously closed at $1.60.
Several analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Depomed from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a report on Tuesday, August 13th. Mizuho reduced their price target on shares of Depomed from $6.00 to $3.00 and set a “neutral” rating for the company in a research report on Thursday, May 16th.
The business’s fifty day moving average price is $2.76 and its 200 day moving average price is $3.77.
An institutional investor recently raised its position in Depomed stock. Public Employees Retirement System of Ohio grew its holdings in Depomed, Inc. (NYSE:ASRT) by 57.3% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 127,059 shares of the company’s stock after buying an additional 46,300 shares during the period. Public Employees Retirement System of Ohio owned 0.20% of Depomed worth $438,000 at the end of the most recent reporting period.
Depomed Company Profile (NYSE:ASRT)
Assertio Therapeutics, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.
Featured Article: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.